Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

NCT00142428 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00142428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00142428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
October 31, 2008
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma